Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 3, 2016 - Issue 1
Submit an article Journal homepage
879
Views
21
CrossRef citations to date
0
Altmetric
Original Research Articles

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results

Goran Nadir SalihDepartment of Respiratory Medicine, Gentofte University Hospital, Hellerup, DenmarkCorrespondence[email protected]
,
Saher Burhan ShakerDepartment of Respiratory Medicine, Gentofte University Hospital, Hellerup, Denmark
,
Helle Dall MadsenDepartment of Respiratory Medicine, Odense University Hospital, Odense, Denmark
&
Elisabeth BendstrupDepartment of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
Article: 32608 | Received 15 Jun 2016, Accepted 17 Aug 2016, Published online: 09 Sep 2016

References

  • Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, etal. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788–824.
  • European Medicines Agency (EMA). Esbriet. CHMP public assessment report EMA/CHMP/115147/2011. Available from: www.ema.europe.eu [cited 10 April 2016]..
  • Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, etal. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011; 377: 1760–9.
  • Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, etal. Double-blind, placebo – controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040–7.
  • Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, etal. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821–9.
  • King TE Jr , Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, etal. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083–92.
  • Spagnolo P, Del Giovani C, Luppi F, Cerri S, Balduzzi S, Walters EH, etal. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010 9 003134.
  • Wijsenbeek MS, Van Beek FT, Geel AL. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands. Am J Respir Crit Care Med. 2013; 187: A4340.
  • Ravaglia C, Gurioli C, Romagnoli M. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series. Eur Respir J. 2013; 42(Suppl. 57): 3370.
  • Nieto BMA, Valenzuela C, Rivera OP. Pirfenidone in idiopathic pulmonary fibrosis (IPF): early Spanish experience with the European Named patient program (NPP). Eur Respir J. 2013; 42(Suppl. 57): 2361.
  • Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of Pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013; 107: 1431–7.
  • Oltmanns U, Kahn N, Palmowski K, Träger A, Wenz H, Heussel CP, etal. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung disease. Respiration. 2014; 88: 199–207.
  • Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfendone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014; 108: 224–6.
  • Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, etal. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014; 52: 136–43.
  • Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wohenschr. 2013; 138: 518–23.
  • Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, etal. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med. 2015; 109: 904–13.
  • Loeh B, Drakopanagiotakis F, Bandelli GP, Von der Beck D, Tello S, Cordani E, etal. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015; 191: 110–3.
  • Harari S, Caminati A. Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev. 2015; 24: 420–7.
  • Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015; 24: 58–64.
  • Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJJ, Ferguson J, etal. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014; 31: 375–91.
  • Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011; 20: 85–97.
  • Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-min walk distance are important in diffuse parenchymal lung disease. Respir Med. 2009; 103: 1430–5.
  • Wigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, etal. Six-minute walk test in idiopathic pulmonary fibrosis: longitudinal changes and minimal important difference. Thorax. 2010; 65: 173–7.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.